FindTrial
Sign In

Nomlabofusp

DRUG3 trials

Sponsors

Larimar Therapeutics Inc., Larimar Therapeutics, Inc.

Conditions

000FXN. Friedreich’s ataxia is a rareFriedreich AtaxiaFriedreich's AtaxiaFriedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial proteinand a carrier frequency of ~1:85.multisystem disease with an incidence that is estimated to be 1:29progressive

Phase 1

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
TerminatedNCT06681766
Larimar Therapeutics, Inc.Friedreich Ataxia
Start: 2024-12-06End: 2025-04-27Updated: 2026-07-10

Phase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia
Not yet recruitingCTIS2025-521628-31-00
Larimar Therapeutics Inc.000, and a carrier frequency of ~1:85., Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein +3
Target: 18Updated: 2026-04-16
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
RecruitingNCT07778836
Larimar Therapeutics, Inc.Friedreich Ataxia, Friedreich's Ataxia
Start: 2026-08-05End: 2029-12-01Target: 150Updated: 2026-08-31